Free Trial
NASDAQ:TKNO

Alpha Teknova (TKNO) Stock Price, News & Analysis

Alpha Teknova logo
$7.73 +0.49 (+6.77%)
(As of 12/20/2024 05:16 PM ET)

About Alpha Teknova Stock (NASDAQ:TKNO)

Key Stats

Today's Range
$7.28
$8.08
50-Day Range
$5.69
$8.81
52-Week Range
$1.15
$8.91
Volume
322,266 shs
Average Volume
229,707 shs
Market Capitalization
$412.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

Alpha Teknova Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
10th Percentile Overall Score

TKNO MarketRank™: 

Alpha Teknova scored higher than 10% of companies evaluated by MarketBeat, and ranked 905th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alpha Teknova has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Alpha Teknova has received no research coverage in the past 90 days.

  • Read more about Alpha Teknova's stock forecast and price target.
  • Earnings Growth

    Earnings for Alpha Teknova are expected to grow in the coming year, from ($0.58) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alpha Teknova is -10.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alpha Teknova is -10.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Alpha Teknova has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.68% of the float of Alpha Teknova has been sold short.
  • Short Interest Ratio / Days to Cover

    Alpha Teknova has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alpha Teknova has recently increased by 4.13%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alpha Teknova does not currently pay a dividend.

  • Dividend Growth

    Alpha Teknova does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.68% of the float of Alpha Teknova has been sold short.
  • Short Interest Ratio / Days to Cover

    Alpha Teknova has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Alpha Teknova has recently increased by 4.13%, indicating that investor sentiment is decreasing.
  • Search Interest

    3 people have searched for TKNO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Alpha Teknova to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alpha Teknova insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.20% of the stock of Alpha Teknova is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 13.81% of the stock of Alpha Teknova is held by institutions.

  • Read more about Alpha Teknova's insider trading history.
Receive TKNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Teknova and its competitors with MarketBeat's FREE daily newsletter.

TKNO Stock News Headlines

TD Cowen Reaffirms Their Buy Rating on Alpha Teknova (TKNO)
70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Alpha Teknova Reports Strong Q3 Revenue Growth
Teknova Reports Third Quarter 2024 Financial Results
See More Headlines

TKNO Stock Analysis - Frequently Asked Questions

Alpha Teknova's stock was trading at $3.73 at the start of the year. Since then, TKNO shares have increased by 107.2% and is now trading at $7.73.
View the best growth stocks for 2024 here
.

Alpha Teknova, Inc. (NASDAQ:TKNO) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.04. The company had revenue of $9.58 million for the quarter, compared to analyst estimates of $9.30 million. Alpha Teknova had a negative trailing twelve-month return on equity of 35.30% and a negative net margin of 87.17%.

Alpha Teknova (TKNO) raised $90 million in an IPO on Friday, June 25th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share.

Top institutional shareholders of Alpha Teknova include Roubaix Capital LLC (0.78%), Point72 Asset Management L.P. (0.57%), Conestoga Capital Advisors LLC (0.57%) and Parkman Healthcare Partners LLC (0.47%). Insiders that own company stock include Telegraph Hill Partners Iv, L, Ted Davis, J Matthew Mackowski, Stephen Gunstream, Matthew Lowell, Damon Terrill, Lisa Hood and Ken Gelhaus.
View institutional ownership trends
.

Shares of TKNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alpha Teknova investors own include Myomo (MYO), Cassava Sciences (SAVA), Heron Therapeutics (HRTX), Taboola.com (TBLA), Ultralife (ULBI), NVIDIA (NVDA) and Sensus Healthcare (SRTS).

Company Calendar

Last Earnings
11/07/2024
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TKNO
Fax
N/A
Employees
240
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
-35.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-36,780,000.00
Pretax Margin
-88.14%

Debt

Sales & Book Value

Annual Sales
$36.35 million
Book Value
$2.21 per share

Miscellaneous

Free Float
45,205,000
Market Cap
$412.07 million
Optionable
Not Optionable
Beta
0.37
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:TKNO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners